Multiple aspects of matrix stiffness in cancer progression.

ECM addiction desmoplasia drivers matrisome matrix stiffness

Journal

Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867

Informations de publication

Date de publication:
2024
Historique:
received: 25 03 2024
accepted: 27 05 2024
medline: 17 7 2024
pubmed: 17 7 2024
entrez: 17 7 2024
Statut: epublish

Résumé

The biophysical and biomechanical properties of the extracellular matrix (ECM) are crucial in the processes of cell differentiation and proliferation. However, it is unclear to what extent tumor cells are influenced by biomechanical and biophysical changes of the surrounding microenvironment and how this response varies between different tumor forms, and over the course of tumor progression. The entire ensemble of genes encoding the ECM associated proteins is called matrisome. In cancer, the ECM evolves to become highly dysregulated, rigid, and fibrotic, serving both pro-tumorigenic and anti-tumorigenic roles. Tumor desmoplasia is characterized by a dramatic increase of α-smooth muscle actin expressing fibroblast and the deposition of hard ECM containing collagen, fibronectin, proteoglycans, and hyaluronic acid and is common in many solid tumors. In this review, we described the role of inflammation and inflammatory cytokines, in desmoplastic matrix remodeling, tumor state transition driven by microenvironment forces and the signaling pathways in mechanotransduction as potential targeted therapies, focusing on the impact of qualitative and quantitative variations of the ECM on the regulation of tumor development, hypothesizing the presence of matrisome drivers, acting alongside the cell-intrinsic oncogenic drivers, in some stages of neoplastic progression and in some tumor contexts, such as pancreatic carcinoma, breast cancer, lung cancer and mesothelioma.

Identifiants

pubmed: 39015505
doi: 10.3389/fonc.2024.1406644
pmc: PMC11249764
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

1406644

Informations de copyright

Copyright © 2024 Mancini, Gentile, Pentimalli, Cortellino, Grieco and Giordano.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.

Auteurs

Alessandro Mancini (A)

Department of Translational Medical Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy.
BioUp Sagl, Lugano, Switzerland.

Maria Teresa Gentile (MT)

Department of Environmental, Biological and Pharmaceutical Sciences and Technologies, University of Campania "Luigi Vanvitelli", Caserta, Italy.

Francesca Pentimalli (F)

Department of Medicine and Surgery, LUM University "Giuseppe De Gennaro," Casamassima, Bari, Italy.

Salvatore Cortellino (S)

Laboratory of Molecular Oncology, Responsible Research Hospital, Campobasso, Italy.
Scuola Superiore Meridionale (SSM), Clinical and Translational Oncology, Naples, NA, Italy.
Sbarro Health Research Organization (S.H.R.O.) Italia Foundation ETS, Candiolo, TO, Italy.

Michele Grieco (M)

Department of Environmental, Biological and Pharmaceutical Sciences and Technologies, University of Campania "Luigi Vanvitelli", Caserta, Italy.

Antonio Giordano (A)

Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA, United States.
Department of Medical Biotechnologies, University of Siena, Siena, Italy.

Classifications MeSH